Achalasia - An Update.
- Author:
Joel E RICHTER
- Publication Type:Review
- Keywords:
Achalasia;
Balloon dilation;
Esophageal sphincter lower;
Muscle, smooth;
Botulinum toxin
- MeSH:
Barium;
Botulinum Toxins;
Deglutition;
Deglutition Disorders;
Esophageal Achalasia;
Esophageal Motility Disorders;
Esophageal Sphincter, Lower;
Female;
Fundoplication;
Humans;
Male;
Manometry;
Muscle, Smooth;
Prognosis;
Relaxation
- From:Journal of Neurogastroenterology and Motility
2010;16(3):232-242
- CountryRepublic of Korea
- Language:English
-
Abstract:
Achalasia is an esophageal motility disorder of unknown cause, characterized by aperistalsis of the esophageal body and impaired lower esophageal sphincter relaxation. Patients present at all ages, primarily with dysphagia for solids/liquids and bland regurgitation. The diagnosis is suggested by barium esophagram and confirmed by esophageal manometry. Achalasia cannot be cured. Instead, our goal is to relieve symptoms, improve esophageal emptying and prevent the development of megaesophagus. The most successful therapies are pneumatic dilation and surgical myotomy. The overall success rate of graded pneumatic dilation is 78%, with women and older patients responding best. Laparoscopic myotomy, usually combined with a partial fundoplication, has an overall success rate of 87%. Young patients, especially men, are the best candidates for surgical myotomy. Botulinum toxin injection into the lower esophageal sphincter and smooth muscle relaxants are usually reserved for older patients or those with co-morbid illness. The prognosis for achalasia patients to return to near normal swallowing is good, but the disease is rarely "cured" with a single procedure and intermittent touch-up procedures may be required.
